Object identification in simultanagnosia: When wholes are not the sum of their parts

Abstract

We examined object identification in two simultanagnosic patients, ES and GK. We show that the patients tended to identify animate objects more accurately than inanimate objects (Experiments 1 and 4). The patients also showed relatively good identification of objects that could be recognised from their global shape, but not objects whose recognition depended on their internal detail (Experiment 2). Indeed, the presence of local segmentation cues disrupted global identification (Experiment 3). Identification was aided, though, by the presence of surface colour and texture (Experiment 4). We suggest that the patients could derive global representations of objects that served to recognise animate items. In contrast, they were impaired at coding parts-based representations for the identification of inanimate objects.     

Action naming with impaired semantics: Neuropsychological evidencecontrasting naming and reading for objects and verbs

We contrast naming from pictures, and reading words, for objects and verbs (actions relating to the objects) in a patient with a large, posterior left-hemisphere lesion. We present evidence for spared picture naming for verbs relative to objects, whilst the opposite pattern of sparing occurred in reading. Objects were also spared relative to verbs in tasks requiring that written words be matched to either pictures or auditory words, in the presence of semantically related or unrelated distractors. We conclude that verb semantics were more impaired than semantic knowledge for objects, and that the better semantic knowledge for object names supported word reading. With pictures, however, action verb retrieval was maintained through a nonsemantic route from vision to action, or though preserved right-hemisphere “action semantics.”     

Life Change Events,Ballistocardiography and Coronary Death

Abstract

Thirty-six men and women who experienced a documented myocardial infarction, half of whom ultimately died from their disease and half of whom survived over a six-year period, provided longitudinal recent life changes and ballistocardiographic data. The 18 patients who died from their coronary disease indicated a significant buildup in life changes which peaked approximately one year prior to death; their serial ballistocardiograms indicated a significant buildup in average force of contraction which was seen to peak approximately six months prior to death. The 18 post-infarction patients who survived the six-year follow-up showed neither a buildup in life change nor a buildup in the ballistocardiographic index of cardiac contraction force. These findings of a life change peak preceding ballistocardiographic evidence of an “overworked” heart are discussed in terms of their possible medical and psychophysiological significances.     

Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculopontine Nucleus in Parkinson Disease

Cholinergic neuronal loss in the pedunculopontine nucleus (PPN) associates with abnormal functions, including certain motor and nonmotor symptoms. This realization has led to low-frequency stimulation of the PPN for treating patients with Parkinson disease (PD) who are refractory to other treatment modalities. However, the molecular mechanisms underlying PPN neuronal loss and the therapeutic substrate for the clinical benefits following PPN stimulation remain poorly characterized, hampering progress toward designing more efficient therapies aimed at restoring the PPN''s normal functions during progressive parkinsonism. Here, we investigated postmortem pathological changes in the PPN of PD cases. Our study detected a loss of neurons producing gamma-aminobutyric acid (GABA) as their output and glycinergic neurons, along with the pronounced loss of cholinergic neurons. These losses were accompanied by altered somatic cell size that affected the remaining neurons of all neuronal subtypes studied here. Because studies showed that mitochondrial dysfunction exists in sporadic PD and in PD animal models, we investigated whether altered mitochondrial composition exists in the PPN. A significant up-regulation of several mitochondrial proteins was seen in GABAergic and glycinergic neurons; however, cholinergic neurons indicated down-regulation of the same proteins. Our findings suggest an imbalance in the activity of key neuronal subgroups of the PPN in PD, potentially because of abnormal inhibitory activity and altered cholinergic outflow.CME Accreditation Statement: This activity (“ASIP 2013 AJP CME Program in Pathogenesis”) has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and the American Society for Investigative Pathology (ASIP). ASCP is accredited by the ACCME to provide continuing medical education for physicians.The ASCP designates this journal-based CME activity (“ASIP 2013 AJP CME Program in Pathogenesis”) for a maximum of 48 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.CME Disclosures: The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.Patients with Parkinson disease (PD) present with a multitude of motor-related disabilities, including progressive resting tremor, rigidity, bradykinesia/akinesia, gait disturbances, and postural instability. In addition, it is recognized increasingly that various nonmotor functions are also left impaired, including mood, cognition, sleep, autonomic nervous system functions, and sensory functions.¹ A neuropathological signature of PD is the progressive deterioration of dopamine-producing neurons in the substantia nigra pars compacta (SNpc).² Although the precise cellular and molecular mechanisms underlying this neuronal death remain unknown, several reports implicate an underlying mitochondrial dysfunction, relating to energy deficits, enhanced production of free-radical species with concomitant oxidative stress,³ proteasomal deregulation,⁴ and neuronal excitotoxicity.⁵Evidence for a mitochondrial-related cause in PD stems from studies reporting on the use of human postmortem brains of patients with PD, which found a deficiency of complex I of the mitochondrial respiratory chain in the SNpc.⁶ Furthermore, outside the central nervous system a mitochondrial respiratory chain complex I deficiency has also been detected in the blood platelets of patients with PD, with some patients who also displayed defects of mitochondrial respiratory chain complexes II and III.⁷ In this regard, Gu et al⁸ found that a mitochondrial DNA (mtDNA) abnormality may underlie this mitochondrial defect in at least a proportion of patients with PD. By contrast, data reporting on mitochondrial respiratory chain defects in skeletal muscle cells of patients with PD remain somewhat more controversial. In this regard, Penn et al⁹ performed 31P magnetic resonance spectroscopy on the resting muscles of patients with PD, to report detecting defects in oxidative phosphorylation in the patients'' musculature, compared with healthy control cases. However, a study by Taylor et al¹⁰ was unable to validate this result. It has been proposed that the conflicting results that report on skeletal mitochondrial defects in patients with PD may relate to either methodological variation for assessing this biochemical defect or may be a reflection of the heterogeneity of the disease.¹¹Further evidence for an association between PD and a mitochondrial defect was obtained from the use of experimental neurotoxins such as rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Use of such toxins mimic parkinsonism in animals to a remarkably accurate extent, with studies showing that the pathological substrate for this defect may be due to the ability of such toxins to inhibit complex I of the mitochondrial respiratory chain.^12,13 Finally, disordered mitochondrial function, including defects in oxidative phosphorylation, are also seen in rare, young-onset genetic forms of PD, such as in patients who harbor mutations in genes such as Parkinson protein 2, E3 ubiquitin protein ligase [parkin (official symbol, PARK2)], parkinson protein 7 [DJ-1, (official symbol, PARK7)], and PTEN (phosphatase and tensin homologue) induced putative kinase 1 (PINK1), where loss of function of the respective protein products associate with deregulation of the mitochondrial quality control pathways of the cells.¹⁴Although the principal motor features of PD stem from reduced dopaminergic innervation of the striatum because of a substantial loss of SNpc dopaminergic neurons, recognition is growing that PD symptoms could result from disruption to multiple neural regions and systems.¹⁵ Although the loss of neurons is most conspicuous in the SNpc, neuronal loss and the presence of intracytoplasmic Lewy bodies (LBs) and Lewy neurites (LNs), composed of aggregation-prone proteins such as α-synuclein (αSYN) form an additional neuropathological hallmark of PD¹⁶ and have been observed in brain regions as diverse as the dorsal motor nucleus of vagus of the medulla, the locus ceruleus in the pons, the raphe nucleus, the basal forebrain, and allocortical regions such as the hippocampus and amygdala.¹⁷ Such widespread distribution of PD pathology could correlate with the variety of motor and nonmotor symptoms observed in patients with PD.¹⁸ PD-related pathologies that affect regions other than the dopaminergic-rich SNpc suggest that, although treatments that target only the nigrostriatal dopaminergic system could substantially benefit patients with PD, they are unlikely to completely resolve the PD-related deficit.¹⁹One particular brain region, the pedunculopontine nucleus (PPN), located within the lateral tegmental region and spanning the pontine midbrain isthmus, has been deemed critically important for regulating some of the physiological functions that fail during progressive PD. Such functions include regulating the activity of the reticular activating system for controlling rapid eye movement (REM) sleep.²⁰ Interestingly, patients with PD frequently present with abnormal REM muscle tone and concomitant REM sleep behavior disorder (RBD),²¹ which may be due to a loss of PPN cells and their concomitant functions during progressive PD. Moreover, PPN axons project toward and receive input from a variety of brain regions, including the thalamus, SN (both the compacta and reticular part), cortical regions, and spinal cord, all of which are involved in regulating aspects of voluntary motor function.^22–30 The PPN was assigned a role in the onset and progression of PD because of reports that the nucleus undergoes degenerative changes, principally affecting the resident cholinergic neurons.^31,32 The loss of these cells is believed to provide the cellular basis for the gait and postural deficits that patients with PD experience³³ and nonhuman primates rendered parkinsonian via cytotoxic lesions.^34,35 In addition, LBs and LNs are seen within the remaining PPN neurons in the postmortem brains of patients with PD.³⁶ Such findings provided the rationale for the commencement of therapeutic trials of deep brain stimulation of the PPN, with trial results reporting a reduction in gait and postural dysfunction in patients with PD after receiving PPN deep brain stimulation.^37,38Here, we used serially cut sections taken from the postmortem PPN of patients with PD and compared this with elderly, healthy control persons, who died without known neurological or psychiatric deficit. After confirming a decreased number of cholinergic neurons in PD-affected PPNs, as previously reported,^31,32 we studied whether the remaining cholinergic neurons undergo somatic cell size alterations. Because it is unknown whether other, noncholinergic neurons are also lost in the PPN of patients with PD, we next determined whether glycinergic and GABAergic neurons in the PPN also degenerate as a result of PD, and whether the remaining neurons undergo structural alterations. In an attempt to explain the altered cell numbers and cellular structural changes seen in the PPN of the present study''s cohort of patients with PD compared with controls, and consistent with the wide amount of literature that suggests an association between PD and mitochondrial dysfunction, we determined whether the loss of different neuronal subpopulations in the PPN is linked to mitochondrial abnormalities.     

How doctors move from generic goals to specific communicative behavior in real practice consultations

Objective

To understand how recommendations for communication can be brought into alignment with clinical communication routines, we explored how doctors select communicative actions during consultations.

Methods

We conducted stimulated recall interviews with 15 GPs (general practitioners), asking them to comment on recordings of two consultations. The data analysis was based on the principles of grounded theory.

Results

A model describing how doctors select communicative actions during consultations was developed. This model illustrates how GPs constantly adapt their selection of communicative actions to their evaluation of the situation. These evaluations culminate in the selection of situation-specific goals. These multiple and often dynamic goals require constant revision and adaptation of communication strategies, leading to constant readjustments of the selection of communicative actions. When selecting consultation goals GPs weigh patients’ needs and preferences as well as the medical situation and its consequences.

Conclusions

GPs’ selection of communicative actions during consultations is situational and goal driven.

Practice implications

To help doctors develop communicative competence tailored to the specific situation of each consultation, holistic communication training courses, which pay attention to the selection of consultation goals and matching communication strategies besides training specific communication skills, seem preferable to current generic communication skills training.     

Using a ‘talk’ model of shared decision making to propose an observation-based measure: Observer OPTION

Objective

To propose a revised Observer OPTION measure of shared decision making.

Methods

We analyzed published models to identify the core components of a parsimonious conceptual framework of shared decision making. By using this framework, we developed a revised measure combining data from an observational study of clinical practice in Canada with our experience of using Observer OPTION^{12 Item}.

Results

Our conceptual framework for shared decision making composed of justifying deliberative work, followed by the steps of describing options, information exchange, preference elicitation, and preference integration. By excluding items in Observer OPTION^{12 Item} that were seldom observed or not aligned to a robust construct, we propose Observer OPTION^{5 Item}.

Conclusion

Although widely used, Observer OPTION^{12 Item} did not give sufficient attention to preference elicitation and integration, and included items that were not specific to a core construct of shared decision making. We attempted to remedy these shortcomings by proposing a shorter, more focused measure.

Practice implications

Observer OPTION^{5 Item} requires evaluation; we hope that it will be useful as both a research tool and as a formative measure of clinical practice.     

Effect of BH4 on blood phenylalanine and tyrosine variations in patients with phenylketonuria

BackgroundIn patients with phenylketonuria, stability of blood phenylalanine and tyrosine concentrations might influence brain chemistry and therefore patient outcome. This study prospectively investigated the effects of tetrahydrobiopterin (BH4), as a chaperone of phenylalanine hydroxylase on diurnal and day-to-day variations of blood phenylalanine and tyrosine concentrations.MethodsBlood phenylalanine and tyrosine were measured in dried blood spots (DBS) four times daily for 2 days (fasting, before lunch, before dinner, evening) and once daily (fasting) for 6 days in a randomized cross-over design with a period with BH4 and a period without BH4. The sequence was randomized. Eleven proven BH4 responsive PKU patients participated, 5 of them used protein substitutes during BH4 treatment. Natural protein intake and protein substitute dosing was adjusted during the period without BH4 in order to keep DBS phenylalanine levels within target range. Patients filled out a 3-day food diary during both study periods. Variations of DBS phenylalanine and Tyr were expressed in standard deviations (SD) and coefficient of variation (CV).ResultsBH4 treatment did not significantly influence day-to-day phenylalanine and tyrosine variations nor diurnal phenylalanine variations, but decreased diurnal tyrosine variations (median SD 17.6 μmol/l, median CV 21.3%, p = 0.01) compared to diet only (median SD 34.2 μmol/l, median CV 43.2%). Consequently, during BH4 treatment diurnal phenylalanine/tyrosine ratio variation was smaller, while fasting tyrosine levels tended to be higher.ConclusionBH4 did not impact phenylalanine variation but decreased diurnal tyrosine and phenylalanine/tyrosine ratio variations, possibly explained by less use of protein substitute and increased tyrosine synthesis.     

“Many miles to go …”: a systematic review of the implementation of patient decision support interventions into routine clinical practice

Background

Two decades of research has established the positive effect of using patient-targeted decision support interventions: patients gain knowledge, greater understanding of probabilities and increased confidence in decisions. Yet, despite their efficacy, the effectiveness of these decision support interventions in routine practice has yet to be established; widespread adoption has not occurred. The aim of this review was to search for and analyze the findings of published peer-reviewed studies that investigated the success levels of strategies or methods where attempts were made to implement patient-targeted decision support interventions into routine clinical settings.

Methods

An electronic search strategy was devised and adapted for the following databases: ASSIA, CINAHL, Embase, HMIC, Medline, Medline-in-process, OpenSIGLE, PsycINFO, Scopus, Social Services Abstracts, and the Web of Science. In addition, we used snowballing techniques. Studies were included after dual independent assessment.

Results

After assessment, 5322 abstracts yielded 51 articles for consideration. After examining full-texts, 17 studies were included and subjected to data extraction. The approach used in all studies was one where clinicians and their staff used a referral model, asking eligible patients to use decision support. The results point to significant challenges to the implementation of patient decision support using this model, including indifference on the part of health care professionals. This indifference stemmed from a reported lack of confidence in the content of decision support interventions and concern about disruption to established workflows, ultimately contributing to organizational inertia regarding their adoption.

Conclusions

It seems too early to make firm recommendations about how best to implement patient decision support into routine practice because approaches that use a ‘referral model’ consistently report difficulties. We sense that the underlying issues that militate against the use of patient decision support and, more generally, limit the adoption of shared decision making, are under-investigated and under-specified. Future reports from implementation studies could be improved by following guidelines, for example the SQUIRE proposals, and by adopting methods that would be able to go beyond the ‘barriers’ and ‘facilitators’ approach to understand more about the nature of professional and organizational resistance to these tools. The lack of incentives that reward the use of these interventions needs to be considered as a significant impediment.

     

Development of a Mycobacterium bovis intranasal challenge model in mice

Tuberculosis caused by infection with Mycobacterium tuberculosis or Mycobacterium bovis remains one of the most important infectious diseases of man and animals. The current vaccine, M. bovis bacille Calmette-Guérin (BCG) demonstrates variable efficacy in humans and cattle, and so an urgent need exists for a new vaccine to replace or supplement BCG. Novel vaccine development requires the availability of a suitable animal model in which to test potential vaccine candidates. Models for tuberculosis vaccine development include mice, guinea pigs, cattle and non-human primates. Murine models provide an economical and easily manipulated tool, but the natural aerosol infection route requires extensive facilities, equipment and validation. We sought to develop a logistically simpler intranasal M. bovis infection model for use in vaccine development for bovine tuberculosis. Intranasal M. bovis infection model in mice demonstrated distinct airway associated, dose related pathology, and was strikingly more virulent than previously employed intravenous infection with M. bovis. BCG vaccination of intranasal challenged mice induced 2 logs of protection with similar kinetics as those displayed in M. tuberculosis aerosol infection models. In conclusion, we report the development of a virulent, robust, stringent, physiological and inexpensive M. bovis intranasal infection model for the screening of potential vaccine candidates against bovine tuberculosis.